ISRCTN ISRCTN14027467
DOI https://doi.org/10.1186/ISRCTN14027467
Secondary identifying numbers CP1
Submission date
12/11/2011
Registration date
16/11/2011
Last edited
12/05/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Malaria is a serious tropical disease spread by mosquitoes. It can be prevented and treated using antimalarial medication, but it often comes back again after treatment. These relapses can be prevented only by the drug primaquine, but there is uncertainty about how long primaquine should be given for. The aim of this study is to compare two widely recommended ways of giving primaquine, a short course and a long course, to see which is better at preventing relapse.

Who can participate?
Patients age over 3 with malaria

What does the study involve?
Participants are randomly allocated to one of three groups. The first group is treated with chloroquine only for 3 days. The second group is treated with chloroquine followed by primaquine for 5 days. The third group is treated with chloroquine followed by primaquine for 14 days. Malaria relapse rate and side effects are assessed in all three groups.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Mahidol University (Thailand)

When is the study starting and how long is it expected to run for?
April 2003 to September 2004

Who is funding the study?
Wellcome Trust (UK)

Who is the main contact?
Prof. Nicholas White
nickw@tropmedres.ac

Contact information

Prof Nicholas White
Scientific

MORU
Faculty of Tropical Medicine
Mahidol University
Bangkok
10400
Thailand

Phone +66 (0)2 203 6301
Email nickw@tropmedres.ac

Study information

Study designOpen-label randomised comparison
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleOpen label comparison of Chloroquine (CQ) alone versus CQ plus 5 days unobserved Primaquine or CQ plus 14 days unobserved primaquine
Study acronymCqPq
Study objectivesRadical cure of vivax malaria requires 14 days primaquine. However, a 5-day regimen has been widely recommended. This trial compares the two radical regimens versus no primaquine.
Ethics approval(s)1. Calcultta School of Tropical Medicine, 2003
2. Faculty of Tropical Medicne, Mahidol University, 08/12/2005, ref: TM-IRB056/2005
Health condition(s) or problem(s) studiedVivax malaria
Intervention1. Chloroquine (25mg base/kg total) only ; 10mg/kg on day 1, 10mg/kg on day 2 then 5mg/kg on day 3
2. Chloroquine (25mg base/kg total as above) followed by primaquine 0.25mg base/kg/day for 5 days-total dose 1.25mg base/kg (75mg in an adult)
3. Chloroquine (25mg base/kg total) followed by primaquine 0.25mg base/kg/ day for 14 days -total dose 3.5mg base/kg (210mg in an adult)
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Chloroquine, primaquine
Primary outcome measureRelapse rate
Secondary outcome measuresAdverse effects
Overall study start date01/04/2003
Completion date01/09/2004

Eligibility

Participant type(s)Patient
Age groupMixed
SexBoth
Target number of participants150
Key inclusion criteria1. Age > 3 years
2. Fully informed consent to long follow-up
3. Acute uncomplicated vivax malaria
4. Not pregnant
Key exclusion criteria1. <3 years
2. Pregnancy
3. Severe disease
Date of first enrolment01/04/2003
Date of final enrolment01/09/2004

Locations

Countries of recruitment

  • India
  • Thailand

Study participating centre

Mahidol University
Bangkok
10400
Thailand

Sponsor information

Mahidol University (Thailand)
University/education

Faculty of Tropical Medicine
420/6 Rajvithi Rd
Bangkok
10400
Thailand

ROR logo "ROR" https://ror.org/01znkr924

Funders

Funder type

Charity

Wellcome Trust (UK) (reference No. 066439/2/01/2)
Private sector organisation / International organizations
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/05/2012 Yes No

Editorial Notes

12/05/2017: Plain English summary added.